次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

メラノーマ(悪性黒色腫)治療薬の世界市場2014-2024年

MELANOMA DRUGS MARKET FORECAST 2014-2024
Opportunities for Leading Companies

出版元:Visiongain(英国)出版元情報LinkIcon
発行年:2014年11月
定価 Single User License(1名様ライセンス) 1,799 GBP(英国ポンド) / Department License(5名様ライセンス) 2,999GBP/ Site License 4,999GBP / Global Site License 6,999GBP
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※デジタル著作権管理/DRM設定有り)
当調査レポートは英文215ページになります。
商品コード:VGN372

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】VGN372_Melanoma_thumbnail.jpg
メラノーマ(悪性黒色腫)治療薬の世界市場規模は2014年に20億ドルに達すると推計されます。需要の増加基調、保険適用の拡大、近年の新治療導入、強力な研究開発パイプラインなどは2024年に向けて市場の促進要因となるでしょう。当レポートでは、同世界市場予測(2014-24)、セグメント別市場予測、主要製品ブランド別売上予測、リーディング企業動向、研究開発情報、市場動向、専門家インタビューなどを織り交ぜ、概略以下の構成でお届けいたします。

【レポート構成概要】
・メラノーマ(悪性黒色腫)治療薬の世界市場予測2014-2024
・全215ページ、185個のデータ表、グラフ類

・セグメント別市場予測2014-24
- 化学療法メラノーマ薬
- キナーゼ阻害剤
- 免疫療法メラノーマ薬
- その他メラノーマ治療薬

・主要14製品、ブランド別売上予測
- Dabrafenib (Tafinlar)
- Trametinib (Mekinist)
- Vemurafenib (Zelboraf)
- Ipilimumab (Yervoy)
- PegIntron (Sylatron)
- Proleukin (Aldesleukin)
- Pembrolizumab (Keytruda)
- Binimetinib
- Cobimetinib
- Tasigna
- Temodar
- Nivolumab
- T-Vec
- Abraxane

・主要13ヶ国、国別市場予測
- 米国、オーストラリア、日本
- ドイツ、フランス、英国、イタリア、スペイン
- ブラジル、ロシア、インド、中国
- トルコ、その他地域(RoW)

・リーディング企業6社プロフィール、業績、製品ポートフォリオ、研究パイプライン、新製品、M&A、展望
- Bayer AG
- Bristol Myers Squibb
- GSK
- Merck
- Prometheus Laboratories
- Roche

・研究開発(R&D)パイプライン
- キナーゼ阻害剤
- 免疫療法薬剤
- メラノーマワクチン
- 遺伝子治療
- その他メラノーマ治療

・市場動向
- 費用償還、当局規制、特許期限切れ、ジェネリックとの競合
- 生物製剤、標的治療、併用療法の使用
- メラノーマの病因と進行
- 安全性と患者コンプライアンス
- 製品効果を支持する臨床的証拠

・専門家オピニオンインタビュー:
- Dr Jean-Pierre Bizzari, Global Head of Oncology, Celgene Corporation
- Dr Rosalie M. Luiten, Head of the Laboratory of Experimental Dermatology, Dept of Dermatology, Academic Medical Center, University of Amsterdam

・調査結論

visiongain is a trading partner with the US Federal Government
【レポート詳細目次、データ項目一覧(List of Tables)は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

MELANOMA DRUGS MARKET FORECAST 2014-2024
Opportunities for Leading Companies

Table of Contents

1. Report Overview

1.1 Global Melanoma Drugs: Market Overview
1.2 Global Melanoma Drugs Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered By This Analytical Report
1.6 Who Is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. An Introduction to Cancer, Melanoma, and Melanoma Treatments

2.1 Cancer: Physiology, Causes, And Effects
2.1.1 Uncontrolled Growth
2.1.2 Dedifferentiation
2.1.3 Invasiveness And Metastasis
2.1.4 Causes Of Cancer
2.2 Melanoma: A Brief Introduction
2.2.1 Causes Of Melanoma
2.2.2 Symptoms And Appearances Of Melanoma
2.3 Stages Of Melanoma
2.3.1 Early Stage Melanoma
2.3.2 Medium Stage Melanoma
2.3.3 Advanced Melanoma
2.4 The Incidence and Outlook for Melanoma – Global Trends
2.5 Surgery As A Treatment For Melanoma
2.6 The Use Of Radiotherapy In Melanoma Treatment
2.7 Drug Treatments In Melanoma
2.7.1 Traditional Chemotherapy
2.7.2 Immunotherapy
2.7.2.1 Monoclonal Antibodies (mAbs)
2.7.2.2 Cancer Vaccines
2.7.2.3 Non-Specific Immunotherapies
2.8 Market Definition

3. World Melanoma Drugs Market, 2014-2024

3.1 Global Melanoma Drugs: Market Overview
3.1.1 Categorisation Of The Global Melanoma Drugs Market
3.2 The Global Melanoma Market In 2013
3.2.1 Market Dominance Of Immunotherapeutic Drugs And Targeted Therapies
3.3 Global Melanoma Drugs: Market Forecast 2014-2024
3.3.1 Market Sectors That Will Drive Growth
3.3.2 Global Melanoma Drugs Market - Changing Market Shares By Sector 2014-2024

4. Kinase Inhibitors For Melanoma: World Market Analysis and Forecast, 2014-2024

4.1 The Global Market For Melanoma Kinase Inhibitors, 2013
4.1.1 Melanoma Kinase Inhibitors: Global Market Forecast 2014-2024
4.1.2 Melanoma Kinase Inhibitors - Changing Market Shares By Leading Drugs 2014-2024
4.2 Dabrafenib (Tafinlar) – GlaxoSmithKline
4.2.1 Dabrafenib (Tafinlar) – Sales Forecast, 2014-2024
4.3 Trametinib (Mekinist) – GlaxoSmithKline
4.3.1 Trametinib (Mekinist) – Sales Forecast 2014-2024
4.4 Vemurafenib (Zelboraf) – Roche/ Genentech/ Chugai/ Daiichi Sankyo
4.4.1 Vemurafenib (Zelboraf) – Historical Sales Analysis, 2011-2013
4.4.2 Vemurafenib (Zelboraf) – Sales Forecast 2014-2024
4.5 The Market For Other Kinase Inhibitors In Melanoma
4.5.1 Other Kinase Inhibitors – Sales Forecast 2014-2024

5. Immunotherapeutic Agents For Melanoma: World Market Analysis and Forecast, 2014-2024

5.1 The Global Market For Immunotherapeutic Agents In Melanoma, 2013
5.1.1 Melanoma Immunotherapeutic Agents: Global Market Forecast 2014-2024
5.1.2 Melanoma Immunotherapeutic Agents - Changing Market Shares By Leading Drugs 2014-2024
5.2 Ipilimumab (Yervoy) – Bristol Myers Squibb
5.2.1 Ipilimumab (Yervoy) – Historical Sales Analysis, 2011-2013
5.2.2 Ipilimumab (Yervoy) – Sales Forecast 2014-2024
5.3 PegIntron (Peginterferon Alpha-2b; Sylatron, IntronA) – Merck
5.3.1 PegIntron – Historical Sales Analysis, 2011-2013
5.3.2 PegIntron – Sales Forecast 2014-2024
5.4 Proleukin (Aldesleukin) – Prometheus Laboratories/ Novartis
5.4.1 Proleukin (Aldesleukin) – Historical Sales Analysis, 2011-2013
5.4.2 Proleukin (Aldesleukin) – Sales Forecast 2014-2024
5.5 Keytruda (Pembrolizumab) - Merck
5.5.1 Patent Disputes Over Keytruda
5.5.2 Keytruda (Pembrolizumab) – Sales Forecast 2014-2024
5.6 The Market For Other Immunotherapeutic Agents In Melanoma
5.6.1 Other Immunotherapeutic Agents – Sales Forecast 2014-2024

6. Chemotherapeutic Agents For Melanoma: World Market Analysis and Forecast, 2014-2024

6.1 The Global Market For Melanoma Chemotherapeutic Agents, 2013
6.1.1 Melanoma Chemotherapeutic Agents: Global Market Forecast 2014-2024
6.2 Dacarbazine (DTIC-Dome) - Bayer
6.2.1 Possible Combination Therapies Involving Dacarbazine
6.3 Temodar/Temodal (Temozolomide) – Merck
6.3.1 Temodar/Temodal (Temozolomide) – Historical Sales Analysis, 2011-2013
6.3.2 Temodar/Temodal (Temozolomide) – Sales Forecast 2014-2024
6.4 Other Chemotherapeutic Agents In Melanoma Treatment
6.4.1 Cisplatin (Platinol)
6.4.1.1 Cisplatin (Platinol) – Historical Sales Analysis, 2010-2012
6.4.2 Fotemustine
6.4.3 Bleomycin (Blenoxane)
6.4.4 Other Chemotherapeutic Agents – Sales Forecast 2014-2024

7. Leading National Markets for Melanoma Drugs, 2014-2024

7.1 The Melanoma Drugs Market By Region
7.1.1 The Global Distribution of Melanoma Drugs In 2013
7.2 Leading National Markets: Forecast 2014-2024
7.2.1 Changing Market Shares By Region, 2014-2024
7.3 Regional Melanoma Drugs Markets: Analysis And Forecasts, 2014-2024
7.4 United States: The Largest Melanoma Drug Market
7.4.1 US Melanoma Drugs Market: Market Forecast 2014-2024
7.5 The EU5 Markets: Growth Expected In Each Country
7.5.1 EU5 Melanoma Drugs Market: Market Forecast 2014-2024
7.5.1.1 EU5 Markets: Changing Market Shares By Country, 2014-2024
7.5.2 Germany: New Reforms To Medicinal Pricing May Impact Market Entry
7.5.2.1 German Melanoma Drugs Market: Market Forecast 2014-2024
7.5.3 France: Changing Drug Approval Process May Delay Regulatory Submissions
7.5.3.1 French Melanoma Drugs Market: Market Forecast 2014-2024
7.5.4 UK: Cost-Effectiveness Measures Impacting Growth
7.5.4.1 UK Melanoma Drugs Market: Market Forecast 2014-2024
7.5.5 Italy: Economic Recovery To Boost Future Of Oncology
7.5.5.1 Italian Melanoma Drugs Market: Market Forecast 2014-2024
7.5.6 Spain: High Level Of Patient Needs Will Counter Healthcare Rationalisation Measures
7.5.6.1 Spain Melanoma Drugs Market: Market Forecast 2014-2024
7.6 Australia: Highest Melanoma Incidence Rate Globally
7.6.1 Australian Melanoma Drugs Market: Market Forecast 2014-2024
7.7 Japan: Openness To Innovation Will Drive Revenue Increase
7.7.1 Japanese Melanoma Drugs Market: Market Forecast 2014-2024
7.8 China: Heavy Reliance On Traditional Herbal Remedies
7.8.1 Chinese Melanoma Drugs Market: Market Forecast 2014-2024
7.9 India: Contrasting Effects Of A Growing Population And Weak IP Protection
7.9.1 Indian Melanoma Drugs Market: Market Forecast 2014-2024
7.10 Brazil: Political Mandates And Economic Development Will Stimulate Growth
7.10.1 Brazilian Melanoma Drugs Market: Market Forecast 2014-2024
7.11 Turkey: Population Growth And Migration Will Be Tools For Growth
7.11.1 Turkish Melanoma Drugs Market: Market Forecast 2014-2024
7.12 Russia: High Income Nation With Low Per-Capita Healthcare Spending
7.12.1 Russian Melanoma Drugs Market: Market Forecast 2014-2024
7.13 Rest of the World
7.13.1 Rest of the World Melanoma Drugs Market: Market Forecast 2014-2024

8. Leading Companies In The Melanoma Drugs Market, 2014

8.1 Melanoma Drugs Market: A Highly Dynamic Market Space
8.2 Bayer AG
8.2.1 Bayer Oncology Drug Portfolio, 2014
8.2.2 Bayer Oncology Drug Pipeline, 2014
8.3 Bristol Myers Squibb
8.3.1 Bristol Myers Squibb: Oncology Drug Portfolio, 2014
8.3.2 Bristol Myers Squibb: Oncology Development Pipeline, 2014
8.4 GlaxoSmithKline (GSK)
8.4.1 GSK: Oncology Drug Portfolio, 2014
8.4.2 GSK: Oncology Development Pipeline, 2014
8.4.3 GSK Asset Swap with Novartis to Restructure Consumer Health
8.5 Merck
8.5.1 Merck: Oncology Drugs Portfolio, 2014
8.5.2 Merck: Oncology Development Pipeline, 2014
8.6 Prometheus Laboratories
8.6.1 Prometheus Laboratories: Oncology Portfolio, 2014
8.7 Roche
8.7.1 Roche: Oncology Portfolio, 2014
8.7.2 Roche: Oncology Development Pipeline, 2014

9. Melanoma Drugs: R&D Pipeline, 2014-2024

9.1 Innovative Products Currently In Development Will Drive Growth
9.1.1 Co-Developments And Collaborations Are Crucial For Market Growth
9.2 Developmental Pipeline - Kinase Inhibitors For Melanoma, 2014
9.2.1 Binimetinib (MEK162) – Novartis
9.2.1.1 Binimetinib (MEK162) – Sales Forecast 2014-2024
9.2.2 Cobimetinib - Exelixis /Genentech/ Roche
9.2.2.1 Co-Development And Licensing Agreements For Cobimetinib
9.2.2.2 Clinical Trials And Development Efforts For Cobimetinib
9.2.2.3 Cobimetinib – Sales Forecast 2014-2024
9.2.3 Encorafenib (LGX818) - Novartis
9.2.4 Tasigna (Nilotinib) - Novartis
9.2.4.1 Tasigna - Indications And Market Exclusivity
9.2.4.2 Tasigna In Melanoma
9.2.4.3 Tasigna (Nilotinib) – Sales Forecast 2014-2024
9.3 Developmental Pipeline - Immunotherapeutic Agents In Melanoma, 2014
9.3.1 Genasense (Oblimersen Sodium) - Genta Incorporated
9.3.2 INCB024360 – Incyte Corporation
9.3.3 MEDI4736 – AstraZeneca/ MedImmune
9.3.4 MPDL3280A – Roche/Genentech
9.3.5 Nivolumab (Opdivo) – Bristol Myers Squibb/ Ono Pharmaceutical
9.3.5.1 Nivolumab (Opdivo) – Sales Forecast 2014-2024
9.4 Developmental Pipeline - Vaccine Therapies In Melanoma, 2014
9.4.1 Astuprotimut-R (MAGE-A3 ASCI) - GlaxoSmithKline
9.4.1.1 Clinical Trials And Development Efforts For Astuprotimut
9.4.2 CDX-1401 – Celldex Therapeutics
9.4.3 Talimogene Laherparepvec (T-Vec) - Amgen
9.4.3.1 Clinical Trials And Development Efforts For T-Vec
9.4.3.2 Talimogene Laherparepvec (T-Vec) – Sales Forecast 2014-2024
9.5 Developmental Pipeline - Genetic Therapies In Melanoma, 2014
9.5.1 Allovectin-7 (Velimogene Aliplasmid) - Vical Incorporated
9.5.1.1 Allovectin-7 – Trial Setbacks And Efficacy Issues
9.5.2 Dorgenmeltucel-L – NewLink Genetics Corporation
9.5.2.1 Clinical Trials And Development Efforts For Dorgenmeltucel-L
9.6 Developmental Pipeline - Other Therapies In Melanoma, 2014
9.6.1 Abraxane - Celgene Corporation
9.6.1.1 Clinical Trials And Development Efforts For Abraxane
9.6.1.2 Abraxane – Sales Forecast 2014-2024
9.6.2 Autologous Dendritic Cell-Tumour Cell Immunotherapy – NeoStem

10. Qualitative Analysis for the Global Melanoma Drugs Market, 2014-2024

10.1 Market Factors Influencing The Melanoma Drugs Market
10.2 SWOT Analysis Of The Melanoma Drugs Market, 2014-2024
10.2.1 Strengths
10.2.1.1 Promising Pipeline Candidates Expected To Boost Product Choice And Competitiveness
10.2.1.2 Stratifying Patients Offers Clinical and Commercial Benefits
10.2.1.3 Improved Patient Compliance Offer Added Incentive For Growth
10.2.2 Weaknesses
10.2.2.1 Disease Recurrence And Low Disease Free Survival May Hinder Investments
10.2.2.2 High Development Costs Making Break-Even A Bigger Challenge For Marketed Drugs
10.2.2.3 The Complexity Of Melanoma’s Aetiology
10.2.3 Opportunities
10.2.3.1 Rising Melanoma Incidence Amidst A Rising Global Population Will Stimulate Growth
10.2.3.2 A Shift Towards Personalisation
10.2.3.3 Combination Therapies Bring Additive Benefits
10.2.3.4 Commercial Success Leveraged By Clinical Benefit
10.2.4 Threats
10.2.4.1 Inadequate Reimbursement Levels: Drug Pricing Creating Constraints On Market Growth
10.2.4.2 Melanoma Drugs Face The Prospect Of Generic Erosion Over Time
10.3 Porter’s Five Force Analysis Of The Melanoma Drugs Market, 2014-2024
10.3.1 Threat Of New Entrants: Medium
10.3.2 Threat Of Substitutes: Low
10.3.3 Power Of Suppliers: Medium
10.3.4 Power Of Buyers: Low
10.3.5 Rivalry Among Competitors: Medium

11. Expert Opinions from Our Primary Research

11.1 Interview With Dr Jean-Pierre Bizzari, Global Head Of Oncology, Celgene Corporation
11.1.1 Targeted Therapies And Immune Checkpoints Are Areas For Accelerated Development
11.1.2 The Economic Implications Of Patient Segmentation And Targeted Therapies
11.1.3 On The Possible Combination Between Celgene’s Abraxane And Bristol Myers Squibb’s Nivolumab
11.1.4 On Celgene’s Strategy For Success In Oncology
11.1.5 On The Current Challenges In Oncology And The Possible Solutions To Be Implemented
11.1.6 On Work Being Done to Map Signalling Pathways And Exploit Cellular Mechanisms For Drug Development
11.1.7 The Future Impact Of Regulatory Hurdles and Trial Design On Survival Advantage
11.2 Interview With Dr Rosalie M. Luiten PhD, Head of the Laboratory of Experimental Dermatology, Dept of Dermatology, Academic Medical Center, University of Amsterdam
11.2.1 Stages Of Melanoma And The Currently Available Treatment Options
11.2.2 Recent Developments In Targeted Therapies For Melanoma
11.2.3 Combination Therapies And The Challenge To Increase Durable Response Rate
11.2.4 On The Current Treatment Options For Early Stage Melanoma
11.2.5 On The Rising Popularity Of Immune Checkpoint Blockade In Oncology
11.2.6 Monobenzone Therapy And Its Potential Use As A Melanoma Therapy
11.2.7 On The Interactions Between Monobenzone And Immune Activating Compounds
11.2.8 Future Plans For Monobenzone Therapy As A Melanoma Treatment
11.2.9 On The Link Between Vitiligo And Melanoma
11.2.10 On The Future Trend Of ‘Per-Patient’ Treatment Approaches To Melanoma

12. Conclusions

12.1 Overview Of Current Market Conditions And Market Forecast, 2013-2024
12.2 The US To Remain As The Largest Market
12.3 Australia And Evolving Markets In Countries Such As Brazil And Turkey Will Stimulate Growth
12.4 Personalisation And Targeted Treatments Will Dominate
12.5 Strong Development Pipeline Will Be Crucial To Future Growth

List of Tables

Table 1.1 US Melanoma Incidence and Mortality: Breakdown by Age-Group (%), 2007-2011
Table 1.2 Redacted German Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 1.3 Redacted Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 2.1 The Clark Scale For Grading Melanoma, 2014
Table 2.2 Cancer-Treating Agents: Chemotherapies and Hormone Therapies, 2014
Table 2.3 Cancer-Treating Agents: Immunotherapies and Targeted Therapies, 2014
Table 3.1 The Global Melanoma Drugs Market: Revenue ($m) and Market Shares (%) by Sector, 2013
Table 3.2 The Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Sector, 2013-2024
Table 3.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2018, 2018-2024, 2013-2024
Table 3.4 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
Table 3.5 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2013, 2018, 2024
Table 4.1 The Global Market for Melanoma Kinase Inhibitors: Revenue ($m) and Market Shares (%) For Leading Drugs, 2013
Table 4.2 Global Melanoma Kinase Inhibitors: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 4.3 The Global Melanoma Kinase Inhibitors Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 4.4 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 4.5 Dabrafenib (Tafinlar): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.6 Trametinib (Mekinist): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.7 Vemurafenib (Zelboraf): Historical Sales ($m, AGR%), 2011-2013
Table 4.8 Vemurafenib (Zelboraf): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 4.9 Other Kinase Inhibitors Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.1 The Global Market for Melanoma Immunotherapeutic Agents: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 5.2 Global Melanoma Immunotherapeutic Agents: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 5.3 The Global Melanoma Immunotherapeutic Agents Market: Revenue ($m) by Leading Drugs, 2013, 2018, 2024
Table 5.4 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2013, 2018, 2024
Table 5.5 Ipilimumab (Yervoy): Historical Sales ($m, AGR%), 2011-2013
Table 5.6 Ipilimumab (Yervoy): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.7 PegIntron (Sylatron): Historical Sales ($m, AGR%), 2011-2013
Table 5.8 PegIntron (Sylatron): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.9 Proleukin (Aldesleukin): Historical Sales ($m, AGR%), 2011-2013
Table 5.10 Proleukin (Aldesleukin): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.11 Keytruda (Pembrolizumab): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 5.12 Other Immunotherapeutic Agents: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.1 The Global Market for Melanoma Chemotherapeutic Agents: Revenue ($m) and Market Shares (%) by Leading Drugs, 2013
Table 6.2 Global Melanoma Chemotherapeutic Agents: Market Forecast ($m, AGR%, CAGR%) by Leading Drugs, 2013-2024
Table 6.3 Temodar/Temodal (Temozolomide): Historical Sales ($m, AGR%), 2011-2013
Table 6.4 Temodar/Temodal (Temozolomide): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 6.5 Cisplatin (Paraplatin): Historical Sales ($m, AGR%), 2010-2012
Table 6.6 Other Chemotherapeutic Agents: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.1 The Global Melanoma Drugs Market: Market Size ($m) and Market Share (%) by Region, 2013
Table 7.2 Global Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%) by Region, 2013-2024
Table 7.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2018, 2018-2024, and 2013-2024
Table 7.4 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2013, 2018, and 2024
Table 7.5 US Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.6 US Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.7 EU5 Melanoma Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
Table 7.8 The EU5 Melanoma Drugs Market: Revenue ($m) and Market Share (%) by Country, 2013
Table 7.9 EU5 Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.10 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2013, 2018, 2024
Table 7.11 The German Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.12 The German Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.13 The French Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.14 The French Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.15 The UK Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.16 The UK Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.17 The Italian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.18 The Italian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.19 The Spanish Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.20 The Spanish Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.21 The Australian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.22 The Australian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.23 The Japanese Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.24 The Japanese Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.25 The Chinese Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.26 The Chinese Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.27 The Indian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.28 The Indian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.29 The Brazilian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.30 The Brazilian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.31 The Turkish Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.32 The Turkish Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.33 The Russian Melanoma Drugs Market Forecast: Revenue ($m), Rank, Market Share (%) and CAGR (%), 2013-2024
Table 7.34 The Russian Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 7.35 The Rest of the World Melanoma Drugs Market Forecast: Revenue ($m), Market Share (%) and CAGR (%), 2013-2024
Table 7.36 The Rest of the World Melanoma Drugs Market: Market Forecast ($m, AGR%, CAGR%), 2013-2024
Table 8.1 Bayer: Overview, 2014
Table 8.2 Bayer: Oncology Portfolio, 2014
Table 8.3 Bayer: Oncology Development Pipeline, 2014
Table 8.4 Bristol Myers Squibb (BMS): Overview, 2014
Table 8.5 Bristol Myers Squibb: Oncology Portfolio, 2014
Table 8.6 Bristol Myers Squibb: Oncology Development Pipeline, 2014
Table 8.7 GlaxoSmithKline (GSK): Overview, 2014
Table 8.8 GlaxoSmithKline (GSK): Oncology Portfolio, 2014
Table 8.9 GlaxoSmithKline (GSK): Oncology Pipeline, 2014
Table 8.10 Merck: Overview, 2014
Table 8.11 Merck: Oncology Portfolio, 2014
Table 8.12 Merck: Oncology Pipeline, 2014
Table 8.13 Prometheus Laboratories: Overview, 2014
Table 8.14 Prometheus Laboratories: Drug Portfolio, 2014
Table 8.15 Roche: Overview, 2014
Table 8.16 Roche: Oncology Portfolio, 2014
Table 8.17 Roche: Oncology Pipeline, 2014
Table 9.1 R&D Pipeline For Kinase Inhibitors In Melanoma, 2014
Table 9.2 Binimetinib (MEK162): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.3 Cobimetinib: Potential Combination Therapies, 2014
Table 9.4 Cobimetinib: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.5 Tasigna (Nilotinib): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.6 R&D Pipeline For Immunotherapeutic Agents In Melanoma, 2014
Table 9.7 Nivolumab (Opdivo): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.8 R&D Pipeline For Vaccine Therapies In Melanoma, 2014
Table 9.9 Talimogene Laherparepvec (T-Vec): Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 9.10 R&D Pipeline For Genetic Therapies In Melanoma, 2014
Table 9.11 R&D Pipeline For Other Therapies In Melanoma Treatment, 2014
Table 9.12 Abraxane: Sales Forecast ($m, AGR%, CAGR%), 2013-2024
Table 10.1 Melanoma Drugs: Market Drivers and Restraints 2014-2024
Table 10.2 SWOT Analysis of the Melanoma Drugs Market, 2014-2024
Table 12.1 Global Melanoma Drugs: Market Forecast ($m, CAGR%), 2013, 2018, 2021, 2024
Table 12.2 Global Melanoma Drugs: Market Shares (%) by Region, 2013, 2018, 2021, 2024
Table 12.3 Global Melanoma Drugs: Market Forecast ($m) by Sector, 2013, 2018, 2021, 2024

List of Figures

Figure 1.1 US Melanoma Incidence and Mortality: Breakdown by Age-Group (%), 2007-2011
Figure 1.2 Global Melanoma Drugs Market: Submarkets, 2014
Figure 3.1 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013
Figure 3.2 The Global Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 3.3 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2018
Figure 3.4 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2018-2024
Figure 3.5 The Global Melanoma Drugs Market Forecast: CAGR (%) by Sector, 2013-2024
Figure 3.6 The Global Melanoma Drugs Market: Revenue ($m) by Sector, 2013, 2018, 2024
Figure 3.7 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2013
Figure 3.8 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2018
Figure 3.9 The Global Melanoma Drugs Market: Market Share (%) by Sector, 2024
Figure 4.1 The Global Market for Melanoma Kinase Inhibitors: Revenue ($m) For Leading Drugs, 2013
Figure 4.2 Global Melanoma Kinase Inhibitors: Market Forecast ($m, AGR%), 2013-2024
Figure 4.3 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2013
Figure 4.4 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2018
Figure 4.5 The Global Melanoma Kinase Inhibitors Market: Market Share (%) by Leading Drugs, 2024
Figure 4.6 Dabrafenib (Tafinlar): Sales Forecast ($m, AGR%), 2013-2024
Figure 4.7 Trametinib (Mekinist): Sales Forecast ($m, AGR%), 2013-2024
Figure 4.8 Vemurafenib (Zelboraf): Historical Sales ($m, AGR%), 2011-2013
Figure 4.9 Vemurafenib (Zelboraf): Sales Forecast ($m, AGR%), 2013-2024
Figure 4.10 Other Kinase Inhibitors: Sales Forecast ($m, AGR%), 2013-2024
Figure 5.1 The Global Market for Melanoma Immunotherapeutic Agents: Revenue ($m) by Leading Drugs, 2013
Figure 5.2 Global Melanoma Immunotherapeutic Agents: Market Forecast ($m, AGR%), 2013-2024
Figure 5.3 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2013
Figure 5.4 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2018
Figure 5.5 The Global Melanoma Immunotherapeutic Agents Market: Market Share (%) by Leading Drugs, 2024
Figure 5.6 Ipilimumab (Yervoy): Historical Sales ($m, AGR%), 2011-2013
Figure 5.7 Ipilimumab (Yervoy): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.8 PegIntron (Sylatron): Historical Sales ($m, AGR%), 2011-2013
Figure 5.9 PegIntron (Sylatron): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.10 Proleukin (Aldesleukin): Historical Sales ($m, AGR%), 2011-2013
Figure 5.11 Proleukin (Aldesleukin): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.12 Keytruda (Pembrolizumab): Sales Forecast ($m, AGR%), 2013-2024
Figure 5.13 Other Immunotherapeutic Agents: Sales Forecast ($m, AGR%), 2013-2024
Figure 6.1 The Global Market for Melanoma Chemotherapeutic Agents: Revenue ($m) by Leading Drugs, 2013
Figure 6.2 Global Melanoma Chemotherapeutic Agents: Market Forecast ($m, AGR%), 2013-2024
Figure 6.3 Temodar/Temodal (Temozolomide): Historical Sales ($m, AGR%), 2011-2013
Figure 6.4 Temodar/Temodal (Temozolomide): Sales Forecast ($m, AGR%), 2013-2024
Figure 6.5 Cisplatin (Paraplatin): Historical Sales ($m, AGR%), 2010-2012
Figure 6.6 Other Chemotherapeutic Agents: Sales Forecast ($m, AGR%), 2013-2024
Figure 7.1 The Global Melanoma Drugs Market: Market Size ($m) by Region, 2013
Figure 7.2 US, EU5, Japan, and Australia Melanoma Drugs Market: Market Forecast ($m), 2013-2024
Figure 7.3 Brazil, Russia, India, China, and Turkey Melanoma Drugs Market: Market Forecast ($m), 2013-2024
Figure 7.4 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2018
Figure 7.5 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2018-2024
Figure 7.6 The Global Melanoma Drugs Market Forecast: CAGR (%) by Region, 2013-2024
Figure 7.7 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2013
Figure 7.8 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2018
Figure 7.9 The Global Melanoma Drugs Market Forecast: Market Share (%) by Region, 2024
Figure 7.10 US Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.11 The EU5 Melanoma Drugs Market: Revenues ($m) by Country, 2013
Figure 7.12 Germany, France, UK, Italy, and Spain Melanoma Drugs Market: Market Forecast ($m), 2013-2024
Figure 7.13 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2013
Figure 7.14 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2018
Figure 7.15 The EU5 Melanoma Drugs Market: Market Share (%) by Country, 2024
Figure 7.16 The German Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.17 The French Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.18 The UK Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.19 The Italian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.20 The Spanish Melanoma Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.21 The Australian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.22 The Japanese Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.23 The Chinese Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.24 The Indian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.25 The Brazilian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.26 The Turkish Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.27 The Russian Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 7.28 The Rest of the World Melanoma Drugs Market: Market Forecast ($m, AGR%), 2013-2024
Figure 9.1 Binimetinib (MEK162): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.2 Cobimetinib: Sales Forecast ($m, AGR%), 2013-2024
Figure 9.3 Tasigna (Nilotinib): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.4 Nivolumab (Opdivo): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.5 Talimogene Laherparepvec (T-Vec): Sales Forecast ($m, AGR%), 2013-2024
Figure 9.6 Abraxane: Sales Forecast ($m, AGR%), 2013-2024
Figure 10.1 Porter’s Five Force Analysis of the Melanoma Drugs Market, 2014
Figure 12.1 Global Melanoma Drugs: Market Forecast ($m), 2013, 2018, 2021, 2024
Figure 12.2 Top Selling Melanoma Drugs, 2013
Figure 12.3 Global Melanoma Drugs: Market Forecast ($m) by Sector, 2013-2024

掲載企業リスト

Companies Listed

Abraxis BioScience
Adaptimmune
Algeta ASA
APP Pharmaceuticals
Amgen
AstraZeneca
Bayer
Bedford Laboratories (Hikma Pharmaceuticals)
Boehringer Ingelheim
BioVex Inc
Bristol Myers Squibb
Celgene Corporation
Chiron Corporation (Novartis)
Chugai
Daiichi Sankyo
Exelixis
Endocyte Inc
Genentech (Roche)
Genta Incorporated
GlaxoSmithKline
Incyte Corporation
JenaPharm (Bayer)
Ono Pharmaceutical
OncoMed Pharmaceutical
Onyx Pharmaceuticals
Mayne Pharma
Merck
Mylan Pharmaceuticals
NeoStem Inc
Nestle Health Sciences
NewLink Genetics Corporation
Novartis
Pfizer
Prometheus Laboratories
Roche
Steigerwald Arzneimittelwerk GmbH
Teva Pharmaceuticals
Zymogenetics

Organisations Mentioned In The Report

Academic Medical Center, University of Amsterdam
American Society of Clinical Oncology (ASCO)
American Society of Hematology (ASH)
CancerAustralia
Commision de la Transparence [France]
The National Cancer Institute (SEER) [US]
Food and Drugs Administration (FDA) [US]
European Organisation for the Research and Treatment of Cancer (EORTC)
European Medicines Agency (EMA)
European Society for Medical Oncology (ESMO)
Ludwig Institute for Cancer Research
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (iQWiG) [Germany]
Ministry of Health Labour and Welfare (MHLW) [Japan]
National Institute for Health and Care Excellence (NICE) [UK]
Society for Immunotherapy of Cancer (SITC)
US Patent & Trademark Office
Therapeutic Goods Administration [Australia]
World Health Organisation (WHO)
World Cancer Research Fund International
World Trade Organisation

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

関連レポート紹介

LinkIcon皮膚科用薬剤の世界市場2014-2024年

皮膚科用薬剤への需要増、医療保険適用の拡大、バイオ医薬品の成功、抗菌薬剤耐性などが売上拡大の促進要因となるでしょう。成熟市場国と新興市場国、ともに成長が見込まれますが、特にインド、ブラジル、中国、メキシコにおいて力強い成長が続くと分析しています。

2319881.jpg国内外のスマートグリッド関連ニュース、リサーチ情報等を収集し隔週でお届けいたします。日本そして海外の企業動向、新製品、政府支援、技術開発、規格、導入事例、投資、調査発表など幅広く情報を定期配信いたします。
スマートグリッド・ニュースへLinkIcon


ニュースページへLinkIcon

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。